NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $4.46 -0.06 (-1.33%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$4.43▼$4.7250-Day Range$2.08▼$4.5252-Week Range$2.00▼$7.96Volume1.53 million shsAverage Volume1.73 million shsMarket Capitalization$354.21 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Ocular Therapeutix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside213.9% Upside$14.00 Price TargetShort InterestHealthy5.72% of Shares Sold ShortDividend StrengthN/ASustainability-2.01Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.21) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector242nd out of 950 stocksPharmaceutical Preparations Industry110th out of 442 stocks 3.5 Analyst's Opinion Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Ocular Therapeutix has a forecasted upside of 213.9% from its current price of $4.46.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.72% of the outstanding shares of Ocular Therapeutix have been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 14.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOcular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ocular Therapeutix is -2.01. Previous Next 3.3 News and Social Media Coverage News SentimentOcular Therapeutix has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 2 articles on an average week.Search Interest19 people have searched for OCUL on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows10 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions54.42% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ocular Therapeutix are expected to grow in the coming year, from ($1.21) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 9.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ocular Therapeutix Stock (NASDAQ:OCUL)Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Read More OCUL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCUL Stock News HeadlinesDecember 24, 2023 | americanbankingnews.comOcular Therapeutix (NASDAQ:OCUL) Downgraded by StockNews.comDecember 18, 2023 | finance.yahoo.comOcular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionDecember 18, 2023 | finance.yahoo.comOcular Therapeutix, Inc.'s (NASDAQ:OCUL) 72% Price Boost Is Out Of Tune With RevenuesDecember 17, 2023 | msn.comOcular Therapeutix (OCUL) Price Target Increased by 27.38% to 15.59December 14, 2023 | msn.comBiggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and moreDecember 14, 2023 | msn.comOcular Therapeutix, Esperion Therapeutics among healthcare moversDecember 14, 2023 | msn.comBiggest stock movers today: Adobe, Ocular Therapeutix and moreDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionDecember 14, 2023 | marketwatch.comOcular Therapeutix Shares Fall Premarket After Stock OfferingDecember 14, 2023 | markets.businessinsider.comOcular Therapeutix Prices Public Offering At $3.25/shareDecember 14, 2023 | msn.comOcular Therapeutix prices capital raise of $100.1 million via stock offeringDecember 13, 2023 | marketwatch.comOcular Therapeutix Shares Drop After Public Offering NewsDecember 13, 2023 | msn.comWhat Happened To Ocular Therapeutix Stock After-Hours?December 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)December 6, 2023 | finance.yahoo.comOcular Therapeutix, Inc.'s (NASDAQ:OCUL) large institutional owners must be happy as stock continues to impress, up 56% over the past weekDecember 5, 2023 | markets.businessinsider.comBuy Rating on Ocular Therapeutix: Anticipating Success for Axpaxli Driven by Positive Industry Trends and Promising Clinical DataDecember 4, 2023 | msn.comOcular Therapeutix, EyePoint Pharmaceuticals among healthcare moversNovember 9, 2023 | markets.businessinsider.comStrong Financial Performance and Promising Clinical Trials Prompt Buy Rating for Ocular TherapeutixNovember 8, 2023 | morningstar.comOcular Therapeutix Inc OCULNovember 8, 2023 | finance.yahoo.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | benzinga.comRecap: Ocular Therapeutix Q3 EarningsNovember 7, 2023 | msn.comOcular Therapeutix GAAP EPS of -$0.25 beats by $0.04, revenue of $15.08M misses by $0.08MNovember 7, 2023 | msn.comOcular Therapeutix files for $300M mixed shelfNovember 7, 2023 | finance.yahoo.comOcular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate UpdateNovember 6, 2023 | msn.comOcular Therapeutix Q3 2023 Earnings PreviewNovember 6, 2023 | markets.businessinsider.comHere's what Wall Street expects from Ocular Therapeutix's earningsSee More Headlines Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCUL CUSIPN/A CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees274Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+213.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,040,000.00 Net Margins-116.18% Pretax Margin-116.18% Return on Equity-589.24% Return on Assets-58.66% Debt Debt-to-Equity Ratio9.41 Current Ratio4.03 Quick Ratio3.96 Sales & Book Value Annual Sales$51.49 million Price / Sales6.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book9.70Miscellaneous Outstanding Shares79,420,000Free Float75,051,000Market Cap$354.21 million OptionableOptionable Beta1.07 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Antony Mattessich (Age 55)President, CEO & Director Comp: $1.05MMr. Donald Notman Jr.Chief Financial OfficerDr. Rabia Gurses Ozden M.D. (Age 55)Chief Medical Officer Comp: $621.39kDr. Peter K. Jarrett Ph.D. (Age 66)Chief Scientific Officer Mr. Philip C. Strassburger Esq. (Age 63)General Counsel Comp: $282.61kMr. William H. Ransone IIVice President of Global Sales & MarketingMs. Tracy SmithVice President of Human ResourcesMr. Christopher G. White (Age 61)Chief Business Officer Dr. Karen-Leigh Edwards M.B.A.Ph.D., Senior Vice President of Technical OperationsMr. Steve MeyersSenior Vice President of CommercialMore ExecutivesKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXUroGen PharmaNASDAQ:URGNNature's Sunshine ProductsNASDAQ:NATRMineralys TherapeuticsNASDAQ:MLYSuniQureNASDAQ:QUREView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 8,152 shares on 12/18/2023Ownership: 5.113%Citigroup Inc.Sold 16,013 shares on 12/6/2023Ownership: 0.025%Wellington Management Group LLPBought 24,342 shares on 12/1/2023Ownership: 0.384%Deutsche Bank AGBought 5,964 shares on 11/24/2023Ownership: 0.045%Graham Capital Management L.P.Bought 95,363 shares on 11/22/2023Ownership: 0.120%View All Insider TransactionsView All Institutional Transactions OCUL Stock Analysis - Frequently Asked Questions Should I buy or sell Ocular Therapeutix stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks. What is Ocular Therapeutix's stock price target for 2024? 3 equities research analysts have issued twelve-month price objectives for Ocular Therapeutix's stock. Their OCUL share price targets range from $12.00 to $18.00. On average, they predict the company's share price to reach $14.00 in the next year. This suggests a possible upside of 213.9% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts. How have OCUL shares performed in 2023? Ocular Therapeutix's stock was trading at $2.81 on January 1st, 2023. Since then, OCUL shares have increased by 58.7% and is now trading at $4.46. View the best growth stocks for 2023 here. When is Ocular Therapeutix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our OCUL earnings forecast. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by $0.24. The biopharmaceutical company had revenue of $15.08 million for the quarter, compared to analysts' expectations of $15.41 million. Ocular Therapeutix had a negative trailing twelve-month return on equity of 589.24% and a negative net margin of 116.18%. What ETFs hold Ocular Therapeutix's stock? ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX). How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCUL) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.